The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes and obesity medications ... of the now-famous drugs manufactured by Novo ...

A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...

Bangkok, April 2025 – Chulalongkorn University, in collaboration with Novo Nordisk Pharma (Thailand) Ltd., has officially launched “Chulalongkorn x Novo Nordisk: Enhancing Obesity Management ...

Europe’s largest pharmaceutical firm, Novo Nordisk, saw its stocks tumble 27% in March, marking their worst monthly performance since July 2002. As of market close on 31 March, the Danish firm’s share ...

(Bloomberg) -- As Novo Nordisk A/S shares head for their worst month in more ... Weaker-than-anticipated CagriSema results for patients with diabetes also haven’t helped. “There have been a lot of ...

The study evaluated the once-weekly injectable Ozempic (semaglutide 1.0 mg) in adults with type 2 diabetes ... Food and Drug Administration (FDA). A decision is anticipated in 2025. Novo Nordisk ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case ...